Cargando…

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients

INTRODUCTION: This study compares the expected occurrence of contraindicated drug–drug interactions (XDDIs) when simeprevir (SIM)- or sofosbuvir (SOF)-containing therapy is added to medication profiles of patients with hepatitis C (HCV) monoinfection to quantify, in relative terms, the population-ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Nimish, Nasiri, Mona, Koroglu, Arden, Bliss, Steven, Davis, Melissa, McNutt, Louise-Anne, Miller, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363220/ https://www.ncbi.nlm.nih.gov/pubmed/25708155 http://dx.doi.org/10.1007/s40121-015-0058-x

Ejemplares similares

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C
por: Sarkar, Souvik, et al.
Publicado: (2015)

Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir
por: Ascha, Mustafa, et al.
Publicado: (2015)

Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation
por: Khemichian, Saro, et al.
Publicado: (2015)

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
por: Gaetano, John N
Publicado: (2014)

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis
por: Nguyen, Nghia H, et al.
Publicado: (2016)

Photo-induced drug eruption in a patient on combination simeprevir/sofosbuvir for hepatitis C
por: Eyre, Zachary W., et al.
Publicado: (2016)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
por: Issa, D., et al.
Publicado: (2016)

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
por: Yee, Brittany E, et al.
Publicado: (2016)

Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4
por: Abdel-Moneim, Adel, et al.
Publicado: (2019)

Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir
por: Ramzy, Sherif, et al.
Publicado: (2022)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
por: Walker, David R, et al.
Publicado: (2015)

Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report
por: Obed, Aiman, et al.
Publicado: (2016)

Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Monoinfection Associated with a High Risk of Acute Liver Failure
por: Hatanaka, Takeshi, et al.
Publicado: (2019)

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results
por: Bichoupan, Kian, et al.
Publicado: (2017)

645 Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women
por: Lo Re, Vincent, et al.
Publicado: (2014)

A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection
por: Li, Chen, et al.
Publicado: (2018)

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
por: Maruyama, Anna, et al.
Publicado: (2016)

Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia
por: Papadopoulos, Nikolaos, et al.
Publicado: (2016)

In vitro susceptibility of human Blastocystis subtypes to simeprevir
por: Mossallam, Shereen F., et al.
Publicado: (2021)

Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report
por: Ende, Alexander R., et al.
Publicado: (2015)

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
por: Lawitz, Eric, et al.
Publicado: (2016)

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium
por: Degré, Delphine, et al.
Publicado: (2017)

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
por: Ezzeldin, Essam, et al.
Publicado: (2020)

Simultaneous spectrofluorimetic determination of remdesivir and simeprevir in human plasma
por: El Sharkasy, Mona E., et al.
Publicado: (2022)

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort
por: Laurain, Anne, et al.
Publicado: (2019)

Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
por: Mohamed, Hala, et al.
Publicado: (2022)

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study
por: Kwo, Paul, et al.
Publicado: (2016)

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study
por: Lawitz, Eric, et al.
Publicado: (2020)

Simeprevir for the treatment of hepatitis C virus infection
por: Izquierdo, Laure, et al.
Publicado: (2014)

Simeprevir restores the anti-Staphylococcus activity of polymyxins
por: Wu, Yuan, et al.
Publicado: (2023)

Prevalence and risk factors for patient-reported joint pain among patients with HIV/Hepatitis C coinfection, Hepatitis C monoinfection, and HIV monoinfection
por: Ogdie, Alexis, et al.
Publicado: (2015)

Mathematical processing of absorption as green smart spectrophotometric methods for concurrent assay of hepatitis C antiviral drugs, Sofosbuvir and Simeprevir: application to combined pharmaceutical dosage forms and evaluation of the method greenness
por: Derayea, Sayed M., et al.
Publicado: (2023)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
por: Yang, Young-Mo, et al.
Publicado: (2017)

Untreated depression among persons living with human immunodeficiency virus in Kazakhstan: A cross-sectional study
por: Terloyeva, Dina, et al.
Publicado: (2018)

Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study
por: Alam, Imtiaz, et al.
Publicado: (2016)

Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir
por: Safadi, Rifaat, et al.
Publicado: (2016)

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Langohr, Klaus, et al.
Publicado: (2008)

Chronic hepatitis B virus monoinfection at a university hospital in Zambia
por: Vinikoor, Michael J, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n2bea17lsp1il1mclbcaj6b21t